BCL2 and follicular lymphoma: Together, patient samples of DLBCL, follicular lymphoma, and marginal zone lymphoma were sensitive to combination treatments of venetoclax plus BCLXi or MCL1i, showing cooperative effects with two BCL2 family inhibitors.